Cognetivity Neurosciences (Cognetivity Neurosciences) Cash-to-Debt : 0.01 (As of Oct. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cognetivity Neurosciences's cash to debt ratio for the quarter that ended in Oct. 2023 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Cognetivity Neurosciences couldn't pay off its debt using the cash in hand for the quarter that ended in Oct. 2023.

The historical rank and industry rank for Cognetivity Neurosciences's Cash-to-Debt or its related term are showing as below:

CGNSF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 1.61 Max: No Debt
Current: 0.01

During the past 7 years, Cognetivity Neurosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 1.61.

CGNSF's Cash-to-Debt is ranked worse than
96.66% of 659 companies
in the Healthcare Providers & Services industry
Industry Median: 0.66 vs CGNSF: 0.01

Cognetivity Neurosciences Cash-to-Debt Historical Data

The historical data trend for Cognetivity Neurosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cognetivity Neurosciences Cash-to-Debt Chart

Cognetivity Neurosciences Annual Data

Trend

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.88

4.33

1.06

1.74

Cognetivity Neurosciences Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
Cash-to-Debt	Get a 7-Day Free Trial															2.96	1.74	0.53	0.02	0.01

Competitive Comparison of Cognetivity Neurosciences's Cash-to-Debt

For the Health Information Services subindustry, Cognetivity Neurosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cognetivity Neurosciences's Cash-to-Debt Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's Cash-to-Debt falls into.

Cognetivity Neurosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cognetivity Neurosciences's Cash to Debt Ratio for the fiscal year that ended in Jan. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.672	/	(0.962	+	0)
	=	1.74

Cognetivity Neurosciences's Cash to Debt Ratio for the quarter that ended in Oct. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.012	/	(0.998	+	0.998)
	=	0.01

Cognetivity Neurosciences (OTCPK:CGNSF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cognetivity Neurosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cognetivity Neurosciences (Cognetivity Neurosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (OTCPK:CGNSF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

1UB:Germany CGN:Canada

Address

800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6

Website

https://www.cognetivity.com

Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Cognetivity Neurosciences (Cognetivity Neurosciences) Headlines

From GuruFocus

Three Companies Using AI and Innovation to Lead Healthcare Sector

By ACCESSWIRE AccessWire • 04-12-2019

The Most Innovative Healthcare AI Developments of 2019

By ACCESSWIRE AccessWire • 04-12-2019